Know Cancer

or
forgot password

Phase II Study of Short High-dose CHOP Chemotherapy for Aggressive Non-Hodgkin's Lymphoma


Phase 2
18 Years
65 Years
Not Enrolling
Both
Non-Hodgkin's Lymphoma

Thank you

Trial Information

Phase II Study of Short High-dose CHOP Chemotherapy for Aggressive Non-Hodgkin's Lymphoma


Inclusion Criteria:



- large-cell non-Hodgkin's lymphoma

- IPI low-intermediate, high-intermediate and high or bulky mediastinum

- age 18-65

Exclusion Criteria:

- previous treatment for lymphoma

- serious concurrent systemic disease

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Failure-free survival

Principal Investigator

Ron Epelbaum, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

nonaffiliated

Authority:

Israel: Israeli Health Ministry Pharmaceutical Administration

Study ID:

RonHDCHOP.CTIL

NCT ID:

NCT00192764

Start Date:

December 1996

Completion Date:

September 2010

Related Keywords:

  • Non-Hodgkin's Lymphoma
  • large cell lymphoma
  • CHOP
  • cyclophosphamide
  • high-dose
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location